The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer

[1] Silver DA(1997)Prostate-specific membrane antigen expression in normal and malignant human tissues Clin Cancer Res: Off J Am Assoc Cancer Res 3 81-5

[2] Pellicer I(2014)Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises J Biol Regul Homeost Agents 28 555-63

[3] Fair WR(2007)Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique Histopathology 50 472-83

[4] Heston WD(2004)Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer J Cell Biochem 91 528-39

[5] Cordon-Cardo C(2007)Targeted treatment of prostate cancer J Cell Biochem 102 571-9

[6] Santoni M(2013)Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases Molecules 18 3379-409

[7] Scarpelli M(2015)Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer J Nucl Med: Off Publ Soc Nucl Med 56 914-20

[8] Mazzucchelli R(2015)The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions J Nucl Med: Off Publ Soc Nucl Med 56 1697-705

[9] Lopez-Beltran A(2016)Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer Oncotarget 7 12477-88

[10] Cheng L(2015)Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study EJNMMI Res 5 114-8

[1] Silver DA(1997)Prostate-specific membrane antigen expression in normal and malignant human tissues Clin Cancer Res: Off J Am Assoc Cancer Res 3 81-5

[2] Pellicer I(2014)Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises J Biol Regul Homeost Agents 28 555-63

[3] Fair WR(2007)Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique Histopathology 50 472-83

[4] Heston WD(2004)Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer J Cell Biochem 91 528-39

[5] Cordon-Cardo C(2007)Targeted treatment of prostate cancer J Cell Biochem 102 571-9

[6] Santoni M(2013)Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases Molecules 18 3379-409

[7] Scarpelli M(2015)Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer J Nucl Med: Off Publ Soc Nucl Med 56 914-20

[8] Mazzucchelli R(2015)The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions J Nucl Med: Off Publ Soc Nucl Med 56 1697-705

[9] Lopez-Beltran A(2016)Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer Oncotarget 7 12477-88

[10] Cheng L(2015)Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study EJNMMI Res 5 114-8